Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials

European Journal of Cancer

Volumn 49, Issue 9, 2013, Pages 2116-2125

  Okines, A F C ^a   Gonzalez De Castro, D ^a   Cunningham, D ^a   Chau, I ^a   Langley, R E ^b   Thompson, L C ^b   Stenning, S P ^b   Saffery, C ^a   Barbachano, Y ^a   Coxon, F ^c   Middleton, G ^d   Ferry, D ^e   Crosby, T ^f   Madhusudan, S ^g   Wadsley, J ^h   Waters, J ⁱ   Hall, M ^j   Swinson, D ^k   Robinson, A ^l   Smith, D ^m   Reis Filho, J S ⁿ   Waddell, T S ^a   Puckey, L ^a   Hulkki Wilson, S ^a   Eltahir, Z ^a   Band, M ^a   Wotherspoon, A ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c Northern Centre for Cancer Care   (United Kingdom)

^d ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^e RUSSELLS HALL HOSPITAL   (United Kingdom)

^f VELINDRE CANCER CENTRE   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h WESTON PARK HOSPITAL   (United Kingdom)

ⁱ Kent Oncology Centre   (United Kingdom)

^j FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^k ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^l East Sussex Healthcare NHS Trust   (United Kingdom)

^m CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

Adenocarcinoma; Biomarker; Chemotherapy; EGFR; Gastric; Oesophageal; Oesophagogastric; Palliative; Panitumumab; Peri operative

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADD ON THERAPY; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC ADENOCARCINOMA; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH ADENOCARCINOMA; TREATMENT DURATION; UNDIFFERENTIATED CARCINOMA;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; GENETIC MARKERS; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84877721344     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.007     Document Type: Article

References (36)

1. P.P. Di Fiore, J.H. Pierce, and T.P. Fleming Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells Cell 51 6 1987 1063 1070
2. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 25 2010 2380 2388
3. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 6 2006 567 578
4. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
5. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 2008 1626 1634
6. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 8 2010 753 762
7. A.F. Okines, S.E. Ashley, and D. Cunningham Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial J Clin Oncol 28 25 2010 3945 3950
8. S.H. Lee, J.W. Lee, and Y.H. Soung BRAF and KRAS mutations in stomach cancer Oncogene 22 44 2003 6942 6945
9. F. Lordick, B. Luber, and S. Lorenzen Cetuximab plus oxaliplatin/ leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Br J Cancer 102 3 2010 500 505
10. M. Moehler, A. Mueller, and T. Trarbach Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study Ann Oncol 22 6 2011 1358 1366
11. S.R. Park, M.C. Kook, and I.J. Choi Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients Cancer Chemother Pharmacol 65 3 2010 579 587
12. C. Pinto, F. Di Fabio, and C. Barone Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) Br J Cancer 101 8 2009 1261 1268
13. D.A. Richards, D.M. Kocs, and A.I. Spira Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study ASCO Annual Meeting, Chicago, 2011 J Clin Oncol 2011 [abst. 4015]
14. S. Barbi, I. Cataldo, and G. De Manzoni The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type J Exp Clin Cancer Res 29 2010 32
15. P. Laurent-Puig, A. Cayre, and G. Manceau Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 35 2009 5924 5930
16. Y.J. Zhou, Y.X. Xiong, and X.T. Wu Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer World J Gastroenterol 10 21 2004 3225 3229
17. D. Cunningham, W.H. Allum, and S.P. Stenning Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 1 2006 11 20
18. S. Benlloch, A. Paya, and C. Alenda Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology J Mol Diagn 8 5 2006 540 543
19. T. Nagao, I. Sugano, and Y. Ishida Primary large-cell neuroendocrine carcinoma of the parotid gland: immunohistochemical and molecular analysis of two cases Mod Pathol 13 5 2000 554 561
20. S.D. Richman, M.T. Seymour, and P. Chambers KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 35 2009 5931 5937
21. K. Nosho, T. Kawasaki, and M. Ohnishi PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations Neoplasia 10 6 2008 534 541
22. D.S. Tan, C. Marchio, and R.L. Jones Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients Breast Cancer Res Treat 111 1 2008 27 44
23. A. Dewdney, D. Cunningham, and J. Tabernero Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C) J Clin Oncol 30 14 2012 1620 1627
24. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
25. D. Cunningham, N. Starling, and S. Rao Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 1 2008 36 46
26. L.M. McShane, D.G. Altman, and W. Sauerbrei Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 16 2005 1180 1184
27. B. Luber, J. Deplazes, and G. Keller Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) BMC Cancer 11 2011 509
28. G. Stella, F. Rojas Limpe, and C. Barone KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients ASCO Annual Meeting, Orlando, 2009 J Clin Oncol 1234 2009 1234 [abstr e15503]
29. J.Y. Douillard, S. Siena, and J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 31 2010 4697 4705
30. E. Van Cutsem, C.H. Kohne, and I. Lang Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 15 2011 2011 2019
31. S. Heindl, E. Eggenstein, and S. Keller Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines J Cancer Res Clin Oncol 2012
32. B. Hotz, U. Keilholz, A. Fusi, H.J. Buhr, and H.G. Hotz In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype Gastric Cancer 15 3 2011 252 264
33. J.W. Lee, Y.H. Soung, and S.Y. Kim ERBB2 kinase domain mutation in a gastric cancer metastasis Apmis 113 10 2005 683 687
34. V.S. Li, C.W. Wong, and T.L. Chan Mutations of PIK3CA in gastric adenocarcinoma BMC Cancer 5 2005 29
35. S. Yamaoka, H. Yamamoto, and K. Nosho Genetic and epigenetic characteristics of gastric cancers with JC virus T-antigen World J Gastroenterol 15 44 2009 5579 5585
36. J.W. Lee, Y.H. Soung, and S.Y. Kim PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas Oncogene 24 8 2005 1477 1480